Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Luger, Dror ^a   Yang, Yu an ^a   Raviv, Asaf ^a   Weinberg, Douglas ^a   Banerjee, Subhadra ^a   Lee, Min Jung ^a   Trepel, Jane ^a   Yang, Li ^a   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD79A ANTIGEN; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE SYK; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; BREAST CANCER; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR PROMOTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD11B; ANTIGENS, CD79; B-LYMPHOCYTES; BREAST NEOPLASMS; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL22; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MYELOID CELLS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84885795735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076115     Document Type: Article

References (63)

1. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
2. Sica A, Bronte V, (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
3. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK, (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22: 275-281.
4. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
5. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, et al. (2010) Gr-1+CD11b+ Myeloid Cells Tip the Balance of Immune Protection to Tumor Promotion in the Premetastatic Lung. Cancer Res 70: 6139-6149.
6. Zumsteg A, Christofori G, (2012) Myeloid cells and lymphangiogenesis. Cold Spring Harb Perspect Med 2: a006494.
7. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35-44.
8. Almand B, Clark JI, Nikitina E, van BJ, English NR, et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689.
9. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
10. Huang B, Pan PY, Li Q, Sato AI, Levy DE, et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131.
11. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, et al. (2012) Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 189: 5602-5611.
12. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802.
13. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S, (2012) Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61: 1155-1167.
14. Nagaraj S, Gabrilovich DI, (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16: 348-353.
15. Montero AJ, az-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S, (2012) Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35: 107-115.
16. Sims R, Vandergon VO, Malone CS, (2012) The mouse B cell-specific mb-1 gene encodes an immunoreceptor tyrosine-based activation motif (ITAM) protein that may be evolutionarily conserved in diverse species by purifying selection. Mol Biol Rep 39: 3185-3196.
17. Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H, (1998) Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 92: 3203-3209.
18. Patterson HC, Kraus M, Wang D, Shahsafaei A, Henderson JM, et al. (2011) Cytoplasmic Ig alpha serine/threonines fine-tune Ig alpha tyrosine phosphorylation and limit bone marrow plasma cell formation. J Immunol 187: 2853-2858.
19. Leduc I, Preud'homme JL, Cogne M, (1992) Structure and expression of the mb-1 transcript in human lymphoid cells. Clin Exp Immunol 90: 141-146.
20. Weiss A, Littman DR, (1994) Signal transduction by lymphocyte antigen receptors. Cell 76: 263-274.
21. Monroe JG, (2006) ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 6: 283-294.
22. Kraus M, Pao LI, Reichlin A, Hu Y, Canono B, et al. (2001) Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tail. J Exp Med 194: 455-469.
23. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K, (2004) Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117: 787-800.
24. Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, Burbano-Ceron L, Camacho-Del MO, et al. (2001) Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukemia. Am J Hematol 68: 69-74.
25. Frater JL, Yaseen NR, Peterson LC, Tallman MS, Goolsby CL, (2003) Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage. Arch Pathol Lab Med 127: 356-359.
26. Arber DA, Jenkins KA, Slovak ML, (1996) CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Am J Pathol 149: 1105-1110.
27. Kozlov I, Beason K, Yu C, Hughson M, (2005) CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet 163: 62-67.
28. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
29. Yang L, Huang J, Ren X, Gorska AE, Chytil A, et al. (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
30. Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T, (1997) CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol 9: 1767-1772.
31. Xie H, Ye M, Feng R, Graf T, (2004) Stepwise reprogramming of B cells into macrophages. Cell 117: 663-676.
32. Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, et al. (2003) Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101: 1950-1955.
33. Chiang MY, Monroe JG, (2001) Role for transcription Pax5A factor in maintaining commitment to the B cell lineage by selective inhibition of granulocyte-macrophage colony-stimulating factor receptor expression. J Immunol 166: 6091-6098.
34. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, et al. (2012) Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 42: 2060-2072.
35. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, et al. (2011) Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res 71: 6143-6152.
36. Reichlin A, Gazumyan A, Nagaoka H, Kirsch KH, Kraus M, et al. (2004) A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells. J Exp Med 199: 855-865.
37. Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A, (2007) CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol 128: 306-313.
38. Benlagha K, Guglielmi P, Cooper MD, Lassoued K, (1999) Modifications of Igalpha and Igbeta expression as a function of B lineage differentiation. J Biol Chem 274: 19389-19396.
39. Katsura Y, (2002) Redefinition of lymphoid progenitors. Nat Rev Immunol 2: 127-132.
40. Kawamoto H, Wada H, Katsura Y, (2010) A revised scheme for developmental pathways of hematopoietic cells: the myeloid-based model. Int Immunol 22: 65-70.
41. Pelanda R, Braun U, Hobeika E, Nussenzweig MC, Reth M, (2002) B cell progenitors are arrested in maturation but have intact VDJ recombination in the absence of Ig-alpha and Ig-beta. J Immunol 169: 865-872.
42. Fuentes-Panana EM, Bannish G, Karnell FG, Treml JF, Monroe JG, (2006) Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol 177: 7913-7922.
43. Pike KA, Iacampo S, Friedmann JE, Ratcliffe MJ, (2004) The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol 172: 2210-2218.
44. Matsuo T, Nomura J, Kuwahara K, Igarashi H, Inui S, et al. (1993) Cross-linking of B cell receptor-related MB-1 molecule induces protein tyrosine phosphorylation in early B lineage cells. J Immunol 150: 3766-3775.
45. Schafer ZT, Brugge JS, (2007) IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663.
46. Hong DS, Angelo LS, Kurzrock R, (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110: 1911-1928.
47. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, et al. (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 90: 1343-1355.
48. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, et al. (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47: 570-584.
49. Iliopoulos D, Hirsch HA, Wang G, Struhl K, (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 108: 1397-1402.
50. Abram CL, Lowell CA, (2007) The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE 2007: re2.
51. Hamerman JA, Ni M, Killebrew JR, Chu CL, Lowell CA, (2009) The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells. Immunol Rev 232: 42-58.
52. Hamerman JA, Lanier LL, (2006) Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006: re1.
53. Ivashkiv LB, (2009) Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 10: 340-347.
54. Sancho D, Reis e Sousa, (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30: 491-529.
55. Patterson HC, Kraus M, Kim YM, Ploegh H, Rajewsky K, (2006) The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain. Immunity 25: 55-65.
56. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
57. Woyach JA, Johnson AJ, Byrd JC, (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120: 1175-1184.
58. Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, et al. (2013) A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol 71: 981-990.
59. Day CP, Carter J, Bonomi C, Esposito D, Crise B, et al. (2009) Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res 22: 283-295.
60. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
61. Xu X, Wagner KU, Larson D, Weaver Z, Li C, et al. (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22: 37-43.
62. Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, et al. (2009) Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat.
63. Parish CR, Glidden MH, Quah BJ, Warren HS, (2009) Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol Chapter 4: Unit4.